Clinical Trial Update: Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib with or without irinotecan in gastroesophageal junction and stomach cancers; study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Diffuse Adenocarcinoma of the Stomach
• Gastric Cancer
• Intestinal Adenocarcinoma of the Stomach
• Mixed Adenocarcinoma of the Stomach
• Stage Iiib Gastric Cancer
• Stage Iiic Gastric Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Phase 2 | Status: COMPLETED | Results posted: 2015-06-03